ABSTRACT
PURPOSE: To report toxicity and local control in patients with localized prostate cancer, treated with high dose radiotherapy. MATERIALS AND METHODS: The records of 100 consecutive patients with clinically localized prostate cancer treated between june 2003 and may 2006 were reviewed. They received 80 Gy to the target volume with a biphasic technique (3DCRT + IMRT). The median pretreatment PSA was 9. The median follow-up time was 12 months. RESULTS: Eighteen (18%) developed acute Grade 2 rectal toxicity, and no patient experienced acute grade 3 or higher rectal symptoms. Forty-four (44%) developed acute Grade 2 urinary symptoms while 34% of the patients experienced no GU symptoms (Grade 0) during treatment. Three patients (3%) developed late rectal toxicity grade 2 and eight patients (8%) experienced late urinary toxicity grade 2; any patients experienced more severe symptoms. We recorded biochemical relapse in two patients, both had poor prognostic factors at initial diagnosis of prostate cancer. CONCLUSIONS: The data demonstrate the feasibility and safety of high dose radiotherapy for patients with localized prostate cancer and provide a proof that this method allow safe dose escalation with low severe toxicities to the normal tissues.
Subject(s)
Adenocarcinoma/radiotherapy , Prostatic Neoplasms/radiotherapy , Radiotherapy, Intensity-Modulated , Adenocarcinoma/pathology , Aged , Aged, 80 and over , Feasibility Studies , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/etiology , Humans , Male , Middle Aged , Prostatic Neoplasms/pathology , Radiation Injuries/epidemiology , Radiation Injuries/etiology , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated/adverse effects , Radiotherapy, Intensity-Modulated/methods , Rectum/radiation effects , Retrospective Studies , Urinary Bladder/radiation effects , Urination Disorders/epidemiology , Urination Disorders/etiologyABSTRACT
Objetivo: Determinar la toxicidad local así como la supervivencia de los pacientes con cáncer de próstata tratados con altas dosis de radioterapia. Material y métodos: Entre junio de 2003 y mayo de 2006 100 pacientes fueron sometidos a tratamiento radioterápico por cáncer de prostáta localizado. Se administró una dosis de 80 Gy al target con una técnica de dos fases (CRT+IMRT). El parámetro medio de PSA fue de 9. La media del seguimiento ha sido de 12 meses. Resultados: Dieciocho (18%) de los pacientes desarrollaron toxicidad GI aguda grado 2 y ningún tipo de toxicidad grado 3 o mayor. El 44% de los paciente experimentaron toxicidad GU grado 2 mientras que el 34% de ellos no experimentaron síntomas GU durante el tratamiento. El 3% de los pacientes desarrollaron toxicidad GI grado 2 y el 8% toxicidad GU tardías. Ningun paciente experimentó síntomas mas severos. Se registró recaída bioquímica en dos pacientes. Ambos tenían factores pronósticos de alto riesgo en el momento del diagnóstico de cáncer de próstata. Conclusión: Los datos demuestran la seguridad y eficacia de las altas dosis de radioterapia en los pacientes con cáncer de próstata localizado utilizando una escalada de dosis en el tratamiento con bajos niveles de toxicidad en tejidos normales
Purpose: To report toxicity and local control in patients with localized prostate cancer, treated with high dose radiotherapy. Materials and methods: The records of 100 consecutive patients with clinically localized prostate cancer treated between june 2003 and may 2006 were reviewed. They received 80 Gy to the target volume with a biphasic technique (3DCRT + IMRT). The median pretreatment PSA was 9. The median follow-up time was 12 months. Results: Eighteen (18%) developed acute Grade 2 rectal toxicity, and no patient experienced acute grade 3 or higher rectal symptoms. Forty-four (44%) developed acute Grade 2 urinary symptoms while 34% of the patients experienced no GU symptoms (Grade 0) during treatment. Three patients (3%) developed late rectal toxicity grade 2 and eight patients (8%) experienced late urinary toxicity grade 2; any patients experienced more severe symptoms. We recorded biochemical relapse in two patients, both had poor prognostic factors at initial diagnosis of prostate cancer. Conclusions: The data demonstrate the feasibility and safety of high dose radiotherapy for patients with localized prostate cancer and provide a proof that this method allow safe dose escalation with low severe toxicities to the normal tissues
